Experienced in Myoglobinuria Recurrent

Christa Firbas

Vienna, AT 
Experienced in Myoglobinuria Recurrent
Vienna, AT 
OverviewLocationsClinical Research

Overview

Christa Firbas practices in Vienna, Austria. Ms. Firbas is rated as an Experienced expert by MediFind in the treatment of Myoglobinuria Recurrent. Her top areas of expertise are Togaviridae Disease, Autoimmune Hemolytic Anemia, Myoglobinuria Recurrent, Toxic Shock Syndrome, and Kidney Transplant.

Her clinical research consists of co-authoring 38 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Myoglobinuria Recurrent.

Gender
Female

Locations

Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 2
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Biological, Other
Study Phase: Phase 1
Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Enrollment Status: Completed
Publish Date: January 04, 2022
Intervention Type: Biological
Study Phase: Phase 2
Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers
Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers
Enrollment Status: Completed
Publish Date: October 29, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of G-PUR® on Enteral Lead Isotope 204Pb-absorption
A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of G-PUR® on Enteral Lead Isotope 204Pb-absorption
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Device
Study Phase: Not Applicable
Open-label, Randomized, Crossover-design Bioequivalence Study With Comparing a Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection of Vifor AG in Healthy Male Volunteers
Open-label, Randomized, Crossover-design Bioequivalence Study With Comparing a Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection of Vifor AG in Healthy Male Volunteers
Enrollment Status: Completed
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

38 Total Publications

Osmotic laxatives do not alter dabigatran plasma concentration in healthy volunteers - a randomized, controlled, cross-over trial.
Osmotic laxatives do not alter dabigatran plasma concentration in healthy volunteers - a randomized, controlled, cross-over trial.
Journal: Frontiers in pharmacology
Published: February 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Firbas's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile